Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World - 2Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
- 3Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- 4Instructions to Warmly greet Certainty and Appeal
- 5Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- The top astronomical discoveries of 2025
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- Vote In favor of Your Favored Shimmering Water
- Unwind: Four Extraordinary Spa Resorts On the planet
- Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- Three killed as unfinished building collapses on church service in Ghana
